Background: Immunochemotherapy has become the first-line treatment for initial diagnosed metastatic nasopharyngeal carcinoma (mNPC). Loco-regional radiotherapy combined with systemic chemotherapy significantly improves the survival. However, the safety and efficacy of loco-regional radiotherapy combined with immunochemotherapy remained unknown.
Methods: Patients with de novo mNPC who received immunochemotherapy followed by loco-regional radiotherapy were included from two cancer centers. Toxicity and treatment response were assessed using CTCAE 5.0 and RECIST 1.1, respectively. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method.
Results: From 2019 to 2021, a total of 16 patients were retrospectively analyzed. The median follow-up was 28 months (range 14-47 months). No one died. One-year, 2-year, and 3-year PFS rate was 93.8%, 58.4% and 50.1%, respectively. Radiotherapy-related acute severe (grade 3 or higher) toxicity was dermatitis (1/16, 6.3%) and mucositis (2/16, 12.5%).
Conclusions: Loco-regional radiotherapy provided a promising efficacy with modest toxicity for patients with mNPC who received immunochemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.27665 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of head and neck cancer of unknown primary: A phase IV study by DAHANCA.
Eur J Cancer
December 2024
Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark. Electronic address:
Background: Diagnostic and therapeutic management of patients with head and neck squamous cell carcinoma of unknown primary (HNSCCUP) remains a challenge. The aim of the present phase IV study was to assess adherence to the current Danish guidelines and evaluate the treatment outcome in HNSCCUP patients.
Materials And Methods: Prospectively collected data in the DAHANCA database from patients treated between 2014 and 2020 was evaluated.
the evolution of axillary management in breast cancer has witnessed significant changes in recent decades, leading to an overall reduction in surgical interventions. There have been notable shifts in practice, aiming to minimize morbidity while maintaining oncologic outcomes and accurate staging for newly diagnosed breast cancer patients. These advancements have been facilitated by the improved efficacy of adjuvant therapies.
View Article and Find Full Text PDFOutcomes of Radical Radiotherapy (RT) or Chemoradiotherapy (CRT) in Surgically Inoperable Advanced Oral Cavity Cancer: A Single Center Experience.
Head Neck
December 2024
Department of Radiation Oncology, Tata Medical Center, Kolkata, India.
Background: Patients with locally advanced, surgically unresectable oral squamous cell cancers (SU-OSCC) are often treated with palliative intent. There is limited information on the outcomes of radical intent treatment with radiotherapy (RT) or chemoradiotherapy (CRT).
Methods: We retrospectively examined patients with Stage III/IV previously untreated SU-OSCC treated definitively from 2011 to 2021 in a single institution with RT or CRT with or without neoadjuvant chemotherapy (NACT).
Predicting early stage lung cancer recurrence and survival from combined tumor motion amplitude and radiomics on free-breathing 4D-CT.
Med Phys
December 2024
Computer and Software Engineering Department, Polytechnique Montréal, Montréal, Quebec, Canada.
Background: Cancer control outcomes of lung cancer are hypothesized to be affected by several confounding factors, including tumor heterogeneity and patient history, which have been hypothesized to mitigate the dose delivery effectiveness when treated with radiation therapy. Providing an accurate predictive model to identify patients at risk would enable tailored follow-up strategies during treatment.
Purpose: Our goal is to demonstrate the added prognostic value of including tumor displacement amplitude in a predictive model that combines clinical features and computed tomography (CT) radiomics for 2-year recurrence and survival in non-small-cell lung cancer (NSCLC) patients treated with curative-intent stereotactic body radiation therapy.
Systematic Review of the Comparative Studies of Image-guided Thermal Ablation, Stereotactic Radiosurgery, and Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.
Semin Thorac Cardiovasc Surg
December 2024
Division of Thoracic Surgery, Harvard Medical School and Brigham and Women's Hospital, Boston, MA. Electronic address:
The Clinical Practice Standards Committee of the American Association for Thoracic Surgery assembled an expert panel and conducted a systematic review of the literature detailing studies directly comparing treatment options for high-risk patients with stage I non-small cell lung cancer (NSCLC). A systematic search was performed to identify publications comparing outcomes following image-guided thermal ablation (IGTA), stereotactic ablative radiotherapy (SABR), and sublobar resection-the main treatment options applicable to high-risk patients with stage I NSCLC. There were no publications detailing completed randomized controlled trials comparing these treatment options.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!